Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 4/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | CCR3 | P51677 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.45 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12309441 | 0.91 | OPRM1 (0.47) | OPRM1FAAHCARM1PRMT6 | |
| SCHEMBL13185171 | 0.85 | HTR2A (0.49) | ACHECCR3CARM1PRMT6 | |
| SCHEMBL21443558 | 0.83 | CCR3 (0.45) | ACHECCR3CARM1PRMT6 | |
| SCHEMBL8302415 | 0.83 | OPRM1 (0.51) | OPRM1 | |
| SCHEMBL4040585 | 0.83 | LMNA (0.53) | CCR3KDM4ELMNAMAPTCARM1 | |
| SCHEMBL2056158 | 0.83 | ALDH1A1 (0.61) | CCR3 | |
| SCHEMBL578726 | 0.83 | SLC6A2 (0.52) | ACHECCR3CARM1PRMT6 | |
| SCHEMBL327856 | 0.82 | CCR3 (0.66) | CCR3CARM1PRMT6 | |
| SCHEMBL12830609 | 0.81 | MAOB (0.63) | ACHECARM1PRMT6 | |
| Hydrochloric Acid SCHEMBL7974948 | 0.81 | OPRM1 (0.49) | OPRM1FAAHKDM4ELMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212121-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS | TRINEURO (KR) | 2023-07-06 | — | — | US | disclosed |
| WO-2022145989-A1 | PYRIMIDODIAZEPINE DERIVATIVE AS SELECTIVE PLK1 INHIBITOR | (주) 업테라 | 2022-07-07 | — | — | WO | disclosed |
| EP-3892276-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AS WNT INHIBITORS | BioSplice Therapeutics, Inc. (US) | 2021-10-13 | — | — | EP | disclosed |
| WO-2020210377-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | NUVATION BIO INC. (US) | 2020-10-15 | — | — | WO | disclosed |
| EP-3549934-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | Celgene CAR LLC (BM) | 2019-10-09 | — | — | EP | disclosed |
| US-20170100397-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2017-04-13 | — | — | US | disclosed |
| US-20160303121-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2016-10-20 | — | — | US | disclosed |
| US-9409921-B2 | 2,4-disubstituted pyrimidines as kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-9296737-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-9212181-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-20110002992-A1 | N-SULPHONYLATED AMINO ACID DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2011-01-06 | — | — | US | disclosed |
| US-20110002992-A1 | N-SULPHONYLATED AMINO ACID DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2011-01-06 | — | — | US | disclosed |
| US-20100216871-A1 | USE OF COMPOUNDS HAVING CCR ANTAGONISM | TSUCHIMORI NOBORU | 2010-08-26 | — | — | US | disclosed |
| US-7772251-B2 | N-sulphonylated amino acid derivatives, method for the production and use thereof | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2010-08-10 | — | — | US | disclosed |
| US-7772251-B2 | N-sulphonylated amino acid derivatives, method for the production and use thereof | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2010-08-10 | — | — | US | disclosed |
| EP-1525200-B1 | 2-(3-AMINOARYL)AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITORS | AB SCIENCE (FR) | 2007-10-10 | — | — | EP | disclosed |
| US-20070105861-A1 | NOVEL VANILLOID RECEPTOR LIGANDS AND USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICAL PREPARATIONS | GRUENENTHAL GMBH (DE) | 2007-05-10 | — | — | US | disclosed |
| US-20070055065-A1 | N-sulphonylated amino acid derivatives, method for the production and use thereof | CURACYTE CHEMISTRY GMBH (DE) | 2007-03-08 | — | — | US | disclosed |
| US-20070055065-A1 | N-sulphonylated amino acid derivatives, method for the production and use thereof | CURACYTE CHEMISTRY GMBH (DE) | 2007-03-08 | — | — | US | disclosed |
| WO-2004101507-A2 | N-SULPHONYLATED AMINO ACID DERIVATIVES AND USE THEREOF AS MATRIPTASE INHIBITORS | CURACYTE CHEMISTRY GMBH (DE) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160303121-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | OPRM1 790/4885ACHE 210/4885FAAH 1433/4885 |
| US-20230212121-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS | SLC6A2, SLC6A3, SLC6A4 | OPRM1 935/4885ACHE 26/4885FAAH 195/4885 |
| US-20070055065-A1 | N-sulphonylated amino acid derivatives, method for the production and use thereof | DNPEP, ANPEP, PEPD | OPRM1 3298/4885ACHE 1600/4885FAAH 1463/4885 |
| US-20110002992-A1 | N-SULPHONYLATED AMINO ACID DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF | DNPEP, ANPEP, PEPD | OPRM1 3298/4885ACHE 1600/4885FAAH 1463/4885 |
| US-20070105861-A1 | NOVEL VANILLOID RECEPTOR LIGANDS AND USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICAL PREPARATIONS | TRPV1, TRPV5, TRPV2 | OPRM1 137/4885ACHE 3448/4885FAAH 1223/4885 |
| US-20100216871-A1 | USE OF COMPOUNDS HAVING CCR ANTAGONISM | CCR1, CCR3, CCR2 | OPRM1 1569/4885ACHE 3400/4885FAAH 1976/4885 |
| US-20170100397-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | OPRM1 790/4885ACHE 210/4885FAAH 1433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.